FEMY
Femasys Inc.
There isn't enough reported data to score FEMY yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
FEMY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
FEMY's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
FEMY PE Valuation
FEMY has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
FEMY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect FEMY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
FEMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$14.40 | +$2.00 |
| Q2 2025 | -$17.20 | -$0.40 |
| Q1 2025 | -$18.20 | -$1.20 |
| Q4 2024 | -$17.00 | +$1.60 |
| Q3 2024 | -$16.40 | +$3.20 |
| Q2 2024 | -$16.80 | +$2.60 |
| Q1 2024 | -$17.00 | +$2.40 |
| Q4 2023 | -$18.60 | +$0.60 |
FEMY has the stronger earnings trend. Trailing diluted EPS is down 188% for FEMY versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
FEMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $331.8K | -19% |
| Q1 2026 | $424.9K | +25% |
| Q4 2025 | $813.4K | +40% |
| Q3 2025 | $729.4K | +31% |
| Q2 2025 | $409.3K | +85% |
| Q1 2025 | $341.3K | +26% |
| Q4 2024 | $581.6K | +173% |
| Q3 2024 | $554.9K | +127% |
FEMY's revenue is growing: $331,827 last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1527% | -586 points |
| Q1 2026 | -994% | +606 points |
| Q4 2025 | -568% | +244 points |
| Q3 2025 | -501% | +422 points |
| Q2 2025 | -941% | +1083 points |
| Q1 2025 | -1600% | -323 points |
| Q4 2024 | -812% | +1276 points |
| Q3 2024 | -922% | +748 points |
FEMY's operating margin was −1527% last quarter, down 586 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over FEMY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over FEMY on profitability, with a higher operating margin.
FEMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | +$501.9K |
| Q1 2026 | -$4.2M | +$639.2K |
| Q4 2025 | -$4.3M | +$856.3K |
| Q3 2025 | -$5.6M | +$300.9K |
| Q2 2025 | -$4.4M | +$62.1K |
| Q1 2025 | -$4.9M | -$229.1K |
| Q4 2024 | -$5.2M | -$2.1M |
| Q3 2024 | -$5.9M | -$3M |
FEMY has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over FEMY on cash generation, producing positive trailing cash flow while its opponent burns cash.
FEMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -548K shares |
| 1 year | +167% | +2.1M shares |
| 3 years | +468% | +2.8M shares |
| 5 years | +637% | +2.9M shares |
FEMY has 3M diluted shares, up 167% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | $161,761 |
| Q4 2024 | $30,093 |
| Q3 2024 | — |
| Q2 2024 | $6,593 |
| Q1 2024 | $24,067 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over FEMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
FEMY Net Leverage
FEMY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
FEMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 4.5 | Oversold |
FEMY's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
FEMY PE vs Healthcare Sector
FEMY has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
FEMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 19% below |
| 20 week MA | $2.55 | 45% below |
| 50 week MA | $7.09 | 80% below |
| 100 week MA | $13.3 | 89% below |
| 200 week MA | $17.3 | 92% below |
FEMY is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
FEMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $240.0 | $91.6 | -62% |
| 2022 | $91.6 | $18.6 | -80% |
| 2023 | $18.6 | $19.5 | +4.8% |
| 2024 | $19.5 | $22.6 | +16% |
| 2025 | $22.6 | $14.2 | -37% |
| 2026 YTD | $14.2 | $1.40 | -90% |
FEMY has finished lower in three of the last five years. It's down 90% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over FEMY on returns for 2026, with the stronger performance.